Leerink Partners Initiates Coverage On Atrium Therapeutics with Outperform Rating, Announces Price Target of $25

Leerink Partners analyst Joseph Schwartz initiates coverage on Atrium Therapeutics (NASDAQ:RNA) with a Outperform rating and announces Price Target of $25.